189 related articles for article (PubMed ID: 34289383)
1. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE; Su R; Dong L; Arellano M; Blum WG; Mao H; Lonial S; Stock W; Odenike O; Le Beau M; Boggon TJ; He C; Chen J; Gao X; Levine RL; Chen J
Mol Cell; 2021 Sep; 81(18):3833-3847.e11. PubMed ID: 34289383
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
3. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
6. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL
Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019
[TBL] [Abstract][Full Text] [Related]
7. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Chen D; Xia S; Wang M; Lin R; Li Y; Mao H; Aguiar M; Famulare CA; Shih AH; Brennan CW; Gao X; Pan Y; Liu S; Fan J; Jin L; Song L; Zhou A; Mukherjee J; Pieper RO; Mishra A; Peng J; Arellano M; Blum WG; Lonial S; Boggon TJ; Levine RL; Chen J
Cancer Discov; 2019 Jun; 9(6):756-777. PubMed ID: 30862724
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
[TBL] [Abstract][Full Text] [Related]
9. Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics.
Xu Y; Liu L; Nakamura A; Someya S; Miyakawa T; Tanokura M
Sci Rep; 2017 Aug; 7(1):9785. PubMed ID: 28852116
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
11. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
Elife; 2017 Jun; 6():. PubMed ID: 28653623
[TBL] [Abstract][Full Text] [Related]
12. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
13. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.
Kats LM; Reschke M; Taulli R; Pozdnyakova O; Burgess K; Bhargava P; Straley K; Karnik R; Meissner A; Small D; Su SM; Yen K; Zhang J; Pandolfi PP
Cell Stem Cell; 2014 Mar; 14(3):329-41. PubMed ID: 24440599
[TBL] [Abstract][Full Text] [Related]
14. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
15. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R
Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Clark O; Yen K; Mellinghoff IK
Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
[TBL] [Abstract][Full Text] [Related]
18. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
19. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
20. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
